Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03496662 · ClinicalTrials.gov registry record · Phase 1
BMS-813160 With Nivolumab and Gemcitabine and Nab-paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC)
A Phase 1 study, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT03496662 is a Phase 1 study that has completed, run by Washington University School of Medicine. The registered enrollment target is 40 participants.
The verdict
NCT03496662, a Phase 1 study, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
The purpose of this research study is to learn more about a new combination of drugs being given to treat pancreatic cancer. The drugs being tested are BMS-813160, nivolumab, gemcitabine, and nab-paclitaxel. The investigators will be looking at both the side effects and the way the disease responds to treatment.
Interventions
- PROCEDURE Biopsy
- DRUG Nivolumab
- DRUG Gemcitabine
- DRUG Nab-paclitaxel
- DRUG BMS-813160
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2018-08-31 |
| Est. Completion | 2024-07-25 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03496662
The ClinicalTrials.gov registry entry for NCT03496662 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Biopsy is the first listed.
NCT03496662 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03496662 about?
NCT03496662 is a clinical study titled "BMS-813160 With Nivolumab and Gemcitabine and Nab-paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC)". The purpose of this research study is to learn more about a new combination of drugs being given to treat pancreatic cancer. The drugs being tested are BMS-813160, nivolumab, gemcitabine, and nab-paclitaxel. The investigators will be looking at both the side effects and the way the disease responds ...
What is the current status of trial NCT03496662?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2018-08-31. Estimated completion is 2024-07-25.
What interventions are being tested in trial NCT03496662?
The interventions under investigation include: Biopsy (PROCEDURE), Nivolumab (DRUG), Gemcitabine (DRUG), Nab-paclitaxel (DRUG), BMS-813160 (DRUG).
Who is sponsoring clinical trial NCT03496662?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.